Peer-reviewed veterinary case report
Lokivetmab treatment for itchy skin in dogs review
By B. Mascarenhas, Mariana & Bazaga Botelho, Cristiane·Published in Clínica Veterinária·2019·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Lokivetmab – a new option for the treatment and control of canine atopic dermatitis – review
- Species:
- dog
Plain-English summary
A dog with atopic dermatitis (a skin allergy condition) can now benefit from a new treatment called Lokivetmab, which is a monoclonal antibody specifically designed for dogs. This medication works by targeting a specific molecule involved in the allergic response, helping to reduce itching and improve skin health. Since it's a new option in veterinary medicine, it offers a promising alternative for dogs suffering from this common skin problem. If your dog has been struggling with allergies and skin issues, ask your veterinarian if Lokivetmab could be a good choice for them.
People also search for: dog skin allergies treatment · Lokivetmab for atopic dermatitis · how to help my dog with itching
Abstract
Monoclonal antibodies have been studied in human medicine for a while. They target specific receptors and cytokines, and are highly specific and effective in blocking their target molecule. Lokivetmab is a monoclonal caninised anti-IL-31 antibody that was recently approved for the treatment of atopic dermatitis in dogs. Currently, no other therapeutic monoclonal antibody is used in veterinary medicine. The goal of this review of literature is to updte clinicians on this new biological option for treatment of canine atopic dermatitis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.46958/rcv.2019.xxiv.n.141.p.34-38